| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT07315503 An Open-label Study of GC012F in Rheumatoid Arthritis. |
overall status: "Not Yet Recruiting" → "Withdrawn" |
| 2026-06-11 | NCT07315503 An Open-label Study of GC012F in Rheumatoid Arthritis. |
Enrollment reduced: 9 -> 0 participants |
| 2026-06-10 | NCT07555470 Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma |
Recruitment opened |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Recruitment opened |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Primary endpoint(s) modified |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Enrollment reduced: 30 -> 27 participants |
| 2026-05-14 | NCT06611839 Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed… |
Enrollment reduced: 29 -> 23 participants |
| 2026-05-14 | NCT07454226 ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL |
Recruitment opened |
| 2026-05-14 | NCT07454226 ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL |
Enrollment increased: 30 -> 92 participants |
| 2026-05-14 | NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Recruitment opened |
| 2026-05-14 | NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Enrollment increased: 100 -> 110 participants |
| 2026-05-14 | NCT07495631 Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult… |
Recruitment opened |
| 2026-05-14 | NCT07495631 Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult… |
Primary endpoint(s) modified |
| 2026-05-14 | NCT07495631 Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult… |
Enrollment reduced: 80 -> 43 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07643103 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative… | Phase 2 | Not Yet Recruiting |
| 2026-05-15 | NCT07588945 daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT | Phase 3 | Not Yet Recruiting |
| 2026-05-14 | NCT07585734 Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute… | Phase 1/2 | Withdrawn |
| 2026-05-14 | NCT07585747 A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and… | Phase 2 | Not Yet Recruiting |
| 2026-05-14 | NCT07585760 CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment | Phase 2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07406139 | PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） | Hemophilia | Recruiting |
| NCT04518475 | Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune… | Primary Immune Thrombocytopenia (ITP) | Recruiting |
| Phase 3 | |||
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia… | AML, Adult | Recruiting |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid… | AML | Recruiting |
| NCT07407140 | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated… | AML, Adult | Not Yet Recruiting |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | AML | Not Yet Recruiting |
| NCT07588945 | daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT | Transplant-Related Disorder | Not Yet Recruiting |
| Phase 2 | |||
| NCT07304232 | Post-transplantation Maintenance Therapy With Cidabenamide in Patients With… | Allogeneic Hematopoietic Cell Transplantation (HCT) | Recruiting |
| NCT07362199 | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune… | Immune Thrombocytopenia | Recruiting |
| NCT07362238 | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune… | Immune Thrombocytopenia | Recruiting |
| NCT07234019 | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of… | Immune Thrombocytopenia | Recruiting |
| NCT07297563 | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune… | Immune Thrombocytopenia | Recruiting |
| NCT05870917 | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With… | Plasma Cell Leukemia | Recruiting |
| NCT07441993 | Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL | Marginal Zone Lymphoma | Recruiting |
| NCT07151690 | BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis | Systemic Light Chain Amyloidosis | Recruiting |
| NCT06635681 | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | AML (Acute Myelogenous Leukemia) | Recruiting |
| NCT07261163 | Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell… | Mantle Cell Lymphoma | Recruiting |
| NCT07299149 | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of… | Follicular Lymphoma | Recruiting |
| NCT07585760 | CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment | Multiple Myeloma (MM) | Recruiting |
| NCT07555470 | Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma | Follicular Lymphoma | Recruiting |
| NCT07409454 | MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly… | Multiple Myeloma | Not Yet Recruiting |
| NCT07441967 | The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte… | Hematologic Malignancies | Not Yet Recruiting |
| NCT07443488 | Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line… | HSCT | Not Yet Recruiting |
| NCT07450313 | The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT | HSCT | Not Yet Recruiting |
| NCT07471503 | Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary… | Myelofibrosis (MF) | Not Yet Recruiting |